<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-IPR-15005794</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2015-01-07</date_registration>
      <primary_sponsor>Central South University Xiangya Hospital</primary_sponsor>
      <public_title>Halploidentical hematopoietic stem cell transplant by intra-bone injection for patients with hematologic malignances</public_title>
      <acronym>Haplploidentical-HSCT by IBM</acronym>
      <scientific_title>Halploidentical hematopoietic stem cell transplant by intra-bone injection for patients with hematologic malignances</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2015-03-01</date_enrolment>
      <type_enrolment />
      <target_size>intra-bone injectioin:60;transfusion by venous:60;</target_size>
      <recruitment_status>Pending</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=10218</url>
      <study_type>Interventional study</study_type>
      <study_design>Randomized parallel controlled trial</study_design>
      <phase>III (Phase III study)</phase>
      <hc_freetext>malignant hematologic disorders</hc_freetext>
      <i_freetext>intra-bone injectioin:Intra-bone injection of mononuclear cells from bone marrow;transfusion by venous:transfuse the hematopietic cells by venous;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Bin Fu</firstname>
        <middlename />
        <lastname />
        <address>No.87, Xiangya Rd, Changsha, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 13755006662</telephone>
        <email>xyfubin@126.com</email>
        <affiliation>Central South University Xiangya Hospital</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Bin Fu</firstname>
        <middlename />
        <lastname />
        <address>No.87, Xiangya Rd, Changsha, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 13755006662</telephone>
        <email>xyfubin@126.com</email>
        <affiliation />
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>At the age of 14 years old to 65 years old (14 years old and 65 years old);
According to the classification standard of diagnosis of malignant diseases of the blood system in 2008 edition of WHO, MDS and leukemia patients;
With hematopoietic stem cell transplantation indications but no HLA matched sibling or unrelated donor transplantation; or the condition requirements as soon as possible without looking HLA haploidentical donor opportunity;
The last time to start of chemotherapy into the group of at least 30 days; the last time to the end of chemotherapy into the group of at least 10 days;
The specificity of HCT prognostic index (HCT-CT) of less than 4 (including 4);
Cardiac ejection fraction greater than 50% (including 50%);
The total bilirubin level in the normal 2 times the upper limit of the following; alanine aminotransferase and aspartate aminotransferase levels in the normal 3 times the upper limit of the following;
Diffusion capacity for carbon monoxide (according to hemoglobin level adjusted) greater than 40% (including 40%); forced expiratory volume in one second more than 50% (including 50%);
Creatinine clearance rate greater than 50ml/min;
Signed informed consent.</inclusion_criteria>
      <agemin />
      <agemax />
      <gender>Both</gender>
      <exclusion_criteria>Symptoms of coronary heart disease;
In group 4 weeks before the memory in the central nervous system leukemia (primitive cells in cerebrospinal fluid of positive);
The fitness score less than 70 points;
Viruses, bacteria and fungi uncontrolled infection (Advances in antifungal therapy process still condition);
HIV seropositive;
Other system malignant tumor history;
Pregnant and lactating women;
Do not agree in the trial period and male and female contraception;</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>survival time;disease free survival time;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Death associated with transplant;incidence and degree of graft-versus-host disease;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Institutional surpport</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2015-01-04</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>